The increased disease control rate within HPV-positive cohorts affirms the preferential response that HPV-positive HNSCC has to TGF-β targeting agents, as was also seen in the BA and BCA101 clinical trials. This evidence concerns the gene TGFB1 and head and neck squamous cell carcinoma.